알림

Capricor Therapeutics Inc... (CAPR)

NasdaqGS: CAPR · 실시간 가격 · USD

7.08

-0.37 (-4.97%)

종가 기준: Aug 18, 2026, 3:59 PM

7.90

-1.03%

애프터마켓: 5:19 PM

-4.97% (1D)

매수호가	5.9
시가총액	463.95M
매출 (ttm)	n/a
순이익 (ttm)	-129.42M
베타	0.53
EPS (ttm)	-2.45
P/E (ttm)	n/a
선행 P/E	-5.23
P/B (ttm)	1.65
P/S (ttm)	n/a
Earnings Date	Nov 10, 2026

매도호가	7.4
거래량	8,403,525
평균 거래량 (20일)	4,594,972
시가	7.51
전일 종가	7.45
일중 범위	6.76 - 8.29
52주 범위	2.96 - 40.37
애널리스트	Hold
목표주가	6 (-15.25%)
배당	n/a
배당락일	n/a

CAPR 소개

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 13, 2007

직원 수 231

상장 거래소 NasdaqGS

티커 CAPR

웹사이트 https://www.capricor.com

전체 기업 정보

재무 실적

2025년 Capricor Therapeutics의 매출은 0로, 전년 22.27M 대비 -100% 감소했습니다. 순이익은 -105.04M로, 159.58% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 4명의 투자의견을 종합하면 CAPR 주식의 평균 등급은 "Hold"입니다. 12개월 목표주가는 6로, 최근 주가 대비 15.25% 하락 여력입니다.

주가 전망

어닝 서프라이즈

Capricor Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.7 예상치 하회 -0.12, 및 -32.08% 전년 대비 감소.

다음 실적 발표

Capricor Therapeutics Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · Stocktwits

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

2일 전 · Simply Wall St.

Capricor Therapeutics (CAPR) Faces Class Action Scrutiny, Is The 88% Undervalued Case Credible?

Capricor Therapeutics (CAPR) is back in focus after two securities class action lawsuits accused the company of failing to disclose FDA concerns about changes to the statistical analysis plan for its ...

4일 전 · Simply Wall St.

Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And Lawsuits - What's Changed

In the past week, Capricor Therapeutics reported Q2 2026 results showing a net loss of US$40.73 million and higher per-share losses, while also facing growing legal and regulatory scrutiny over its le...

5일 전 · Stocktwits

CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path

Cantor Fitzgerald upgraded Capricor to ‘Overweight’ from ‘Neutral’ and raised its price target to $28 from $3.50, just weeks after the firm slashed its price target to $3.50 from $62.

5일 전 · BioPharma Dive

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

2 페이지 중 1

Capricor Therapeutics Inc... (CAPR)